e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Diffuse parenchymal lung disease II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Natural history of idiopathic pulmonary fibrosis: Are slowly progressive and rapidly progressive really steady conditions?
E. Balestro, E. Rossi, A. Floriani, C. Rinaldo, F. Lunardi, M. Loy, F. Rea, M. Cosio, M. Saetta, F. Calabrese (Padova, Italy)
Source:
Annual Congress 2012 - Diffuse parenchymal lung disease II
Session:
Diffuse parenchymal lung disease II
Session type:
Thematic Poster Session
Number:
3638
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Balestro, E. Rossi, A. Floriani, C. Rinaldo, F. Lunardi, M. Loy, F. Rea, M. Cosio, M. Saetta, F. Calabrese (Padova, Italy). Natural history of idiopathic pulmonary fibrosis: Are slowly progressive and rapidly progressive really steady conditions?. Eur Respir J 2012; 40: Suppl. 56, 3638
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
A prothrombotic state is associated with increased mortality in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Idiopathic pulmonary fibrosis: a treatable disease?
Source: Eur Respir J 2003 Dec 01;22(6):872-873
Year: 2003
The natural history of progressive fibrosing interstitial lung diseases
Source: Eur Respir J, 55 (6) 2000085; 10.1183/13993003.00085-2020
Year: 2020
Idiopathic pulmonary fibrosis: recent milestones in disease management
Source: Eur Respir Rev 2012; 21: 140
Year: 2012
Severe idiopathic pulmonary fibrosis: what can be done?
Source: Eur Respir Rev, 26 (145) 170047; 10.1183/16000617.0047-2017
Year: 2017
Coexistent pulmonary emphysema delays the decrease in vital capacity in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008
The changing treatment landscape in idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 65-68
Year: 2015
Idiopathic pulmonary fibrosis: another step in understanding the burden of this disease
Source: Eur Respir J 2016; 48: 26-28
Year: 2016
Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm
Source: Eur Respir J 2015; 46: 512-520
Year: 2015
Effect of 24-month Pirfenidone treatment on functional decline in Idiopathic Pulmonary Fibrosis (IPF) patients with rapid and slow disease progression
Source: International Congress 2017 – The wide spectrum of ILDs
Year: 2017
Slow
versus
rapid progressors in idiopathic pulmonary fibrosis
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Idiopathic pulmonary fibrosis: time for greater expectations?
Source: Eur Respir J, 52 (2) 1801312; 10.1183/13993003.01312-2018
Year: 2018
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
Source: Eur Respir J 2007; 30: 835-839
Year: 2007
Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosis
Source: Eur Respir J, 56 (3) 1902058; 10.1183/13993003.02058-2019
Year: 2020
Accelerated variant of idiopathic pulmonary fibrosis: clinical and molecular behaviour
Source: Eur Respir J 2007; 30: Suppl. 51, 488s
Year: 2007
A global registry for idiopathic pulmonary fibrosis: the time is now
Source: Eur Respir J 2014; 44: 273-276
Year: 2014
Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease
Source: Eur Respir Rev 2009; 18: 129-132
Year: 2009
The therapy of idiopathic pulmonary fibrosis: what is next?
Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019
Year: 2019
Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis
Source: Eur Respir J 2013; 42: 916-923
Year: 2013
The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept